Market Overview

UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

Related ALKS
US Stock Futures Rise Ahead Of Economic Data
Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For Alkermes plc

In a report published Thursday, Citigroup analyst Jonathan Eckard reiterated a Buy rating on Alkermes PLC (NASDAQ: ALKS), and raised the price target from $38.00 to $43.00.

In the report, Citigroup noted, “We are adding ALKS to the Citi Focus List and increasing our target price on ALKS to $43 from $38 based on our increased estimates for late-stage programs, introduction of estimates for earlier stage programs, and lower outyear tax rate. We believe there are several ALKS programs with significant commercial potential. Considering the breadth of interesting programs in the company's pipeline, we believe that ALKS' relative valuation is discounted compared to other mid-cap biotech companies within the same range of market capitalization.”

Alkermes PLC closed on Wednesday at $32.62.

Posted-In: Citigroup Jonathan EckardAnalyst Color Price Target Analyst Ratings

 

Related Articles (ALKS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters